


CLAIMS

What is claimed is:

5

1. A compound of Formula I



I

or a pharmaceutically acceptable salt thereof,

wherein:

10

R<sup>1</sup> is independently selected from:

C<sub>5</sub> or C<sub>6</sub> cycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Substituted C<sub>5</sub> or C<sub>6</sub> cycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

C<sub>8</sub>-C<sub>10</sub> bicycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Substituted C<sub>8</sub>-C<sub>10</sub> bicycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

15

5- or 6-membered heterocycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Substituted 5- or 6-membered heterocycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

8- to 10-membered heterobicycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Substituted 8- to 10-membered heterobicycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

20

Substituted phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Naphthyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Substituted naphthyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Substituted 5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

25

8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Substituted 8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Phenyl;

Substituted phenyl;

Naphthyl;

30

Substituted naphthyl;

5- or 6-membered heteroaryl;  
Substituted 5- or 6-membered heteroaryl;  
8- to 10-membered heterobiaryl; and  
Substituted 8- to 10-membered heterobiaryl;

5  $R^2$  is independently selected from:

H;  
C<sub>1</sub>-C<sub>6</sub> alkyl;  
Phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Substituted phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
10 Naphthyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Substituted naphthyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Substituted 5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
15 Substituted 8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Phenyl-O-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Substituted phenyl-O-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Phenyl-S-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Substituted phenyl-S-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
20 Phenyl-S(O)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Substituted phenyl-S(O)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Phenyl-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl); and  
Substituted phenyl-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

$R^{2a}$  is H or C<sub>1</sub>-C<sub>6</sub> alkyl; or

25  $R^2$  and  $R^{2a}$  are taken together with the carbon atom to which they are both bonded to form a group C=C(H) $R^2$ , wherein  $R^2$  is as defined above;

Each substituted  $R^1$  and  $R^2$  group contains from 1 to 4 substituents, each independently on a carbon or nitrogen atom, independently selected from:

C<sub>1</sub>-C<sub>6</sub> alkyl;  
30 CN;  
CF<sub>3</sub>;  
HO;  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-O;


- (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(O)<sub>2</sub>;  
H<sub>2</sub>N;  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-N(H);  
(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>-N;  
5 (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)O-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)O-(1- to 8-membered heteroalkylenyl)<sub>m</sub>;  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)N(H)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)N(H)-(1- to 8-membered heteroalkylenyl)<sub>m</sub>;  
H<sub>2</sub>NS(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
10 (C<sub>1</sub>-C<sub>6</sub> alkyl)-N(H)S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;  
(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>-NS(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;  
3- to 6-membered heterocycloalkyl-(G)<sub>m</sub>;  
Substituted 3- to 6-membered heterocycloalkyl-(G)<sub>m</sub>;  
5- or 6-membered heteroaryl-(G)<sub>m</sub>;  
15 Substituted 5- or 6-membered heteroaryl-(G)<sub>m</sub>;  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-S(O)<sub>2</sub>-N(H)-C(O)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>; and  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-N(H)-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;


wherein each substituent on a carbon atom may further be independently selected from:

- 20 Halo; and  
HO<sub>2</sub>C;

wherein 2 substituents may be taken together with a carbon atom to which they are both bonded to form the group C=O;

- wherein two adjacent, substantially sp<sup>2</sup> carbon atoms may be taken together with a  
25 diradical substituent to form a cyclic diradical selected from:





R is H or C<sub>1</sub>-C<sub>6</sub> alkyl;

5 G is CH<sub>2</sub>; O, S, S(O); or S(O)<sub>2</sub>;

m is an integer of 0 or 1;

Y<sup>1</sup> is O, S, S(O), S(O)<sub>2</sub>, or CH<sub>2</sub>;

Y<sup>5</sup>, Y<sup>6</sup>, and Y<sup>8</sup> are each independently C(R<sup>5</sup>) or N;

R<sup>4</sup> and each R<sup>5</sup> are each independently selected from the groups:







- 10 H;  
CH<sub>3</sub>;  
CH<sub>3</sub>O;  
CH=CH<sub>2</sub>;  
HO;
- 15 CF<sub>3</sub>;  
CN;  
HC(O);  
CH<sub>3</sub>C(O);  
HC(NOH);
- 20 H<sub>2</sub>N;  
(CH<sub>3</sub>)-N(H);  
(CH<sub>3</sub>)<sub>2</sub>-N;  
H<sub>2</sub>NC(O);

$(\text{CH}_3)\text{-N(H)C(O)}$ ; and


$(\text{CH}_3)_2\text{-NC(O)}$ ;

Q is selected from:

- 5             $\text{OC(O)}$ ;  
               $\text{CH(R}^6\text{)C(O)}$ ;  
               $\text{OC(NR}^6\text{)}$ ;  
               $\text{CH(R}^6\text{)C(NR}^6\text{)}$ ;  
               $\text{N(R}^6\text{)C(O)}$ ;  
               $\text{N(R}^6\text{)C(S)}$ ;  
 10            $\text{N(R}^6\text{)C(NR}^6\text{)}$ ;  
               $\text{N(R}^6\text{)CH}_2$ ;  
               $\text{SC(O)}$ ;  
               $\text{CH(R}^6\text{)C(S)}$ ;  
               $\text{SC(NR}^6\text{)}$ ;  
 15            $\text{trans-(H)C=C(H)}$ ;  
               $\text{cis-(H)C=C(H)}$ ;  
               $\text{C}\equiv\text{C}$ ;  
               $\text{CH}_2\text{C}\equiv\text{C}$ ;  
               $\text{C}\equiv\text{CCH}_2$ ;  
 20            $\text{CF}_2\text{C}\equiv\text{C}$ ; and  
               $\text{C}\equiv\text{CCF}_2$ ;



; and



Each R<sup>6</sup> independently is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; benzyl; or 5- or 6-membered heteroaryl;

X is O, S, N(H), or N(C<sub>1</sub>-C<sub>6</sub> alkyl);

Each V is independently C(H) or N;

5 wherein each C<sub>8</sub>-C<sub>10</sub> bicycloalkyl is a bicyclic carbocyclic ring that contains 8-, 9-, or 10-member carbon atoms which are 5,5-fused, 6,5-fused, or 6,6-fused bicyclic rings, respectively, and wherein the ring is saturated or optionally contains one carbon-carbon double bond;

10 wherein each 8- to 10-membered heterobicycloalkyl is a bicyclic ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 S(O)<sub>2</sub>, 1 N, 4 N(H), and 4 N(C<sub>1</sub>-C<sub>6</sub> alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond, and wherein the heterobicycloalkyl is a 5,5-fused, 6,5-fused, or 6,6-fused bicyclic ring, respectively,

15 wherein each heterocycloalkyl is a ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 S(O)<sub>2</sub>, 1 N, 4 N(H), and 4 N(C<sub>1</sub>-C<sub>6</sub> alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond;

20 wherein each 5-membered heteroaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C<sub>1</sub>-C<sub>6</sub> alkyl), and 4 N, and each 6-membered heteroaryl contains carbon atoms and 1 or 2 heteroatoms independently selected from N, N(H), and N(C<sub>1</sub>-C<sub>6</sub> alkyl), and 5- and 6-membered heteroaryl are monocyclic rings;

25 wherein each heterobiaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C<sub>1</sub>-C<sub>6</sub> alkyl), and 4 N, and where the 8-, 9-, and 10-membered heterobiaryl are 5,5-fused, 6,5-fused, and 6,6-fused bicyclic rings, respectively, and wherein at least 1 of the 2 fused rings of a bicyclic ring is aromatic, and wherein when the O

and S atoms both are present, the O and S atoms are not bonded to each other;

wherein with any (C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>-N group, the C<sub>1</sub>-C<sub>6</sub> alkyl groups may be optionally taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocycloalkyl; and wherein each group and each substituent recited above is independently selected.

2. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Y<sup>5</sup>, Y<sup>6</sup>, and Y<sup>8</sup> are each C(R<sup>5</sup>), wherein each R<sup>5</sup> is independently defined as above.

3. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein one of Y<sup>5</sup>, Y<sup>6</sup>, and Y<sup>8</sup> is N and the other two of Y<sup>5</sup>, Y<sup>6</sup>, and Y<sup>8</sup> are C(R<sup>5</sup>), wherein each R<sup>5</sup> is independently defined as above.

4. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is N(R<sup>6</sup>)C(O).

5. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is C≡C.

6. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Y<sup>1</sup> is CH<sub>2</sub>.

7. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Y<sup>1</sup> is O.

8. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Y<sup>1</sup> is S(O)<sub>2</sub>.

9. The compound according to any one of Claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is independently selected from:

Phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Substituted phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
Substituted 5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
5 8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl); and  
Substituted 8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl); and

R<sup>2</sup> is independently selected from:

Phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;  
Substituted phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;  
10 5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;  
Substituted 5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;  
8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>; and  
Substituted 8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;

wherein m is an integer of 0 or 1; and

15 wherein each group and each substituent is independently selected.

10. The compound according to Claim 1, selected from:

3-Benzylidene-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinoline-6-carboxylic  
acid 4-methylsulfanyl-benzylamide;

20 3-(3,5-Difluoro-4-hydroxy-benzyl)-1-methyl-2-oxo-1,2,3,4-tetrahydro-  
quinoline-6-carboxylic acid (pyrimidin-5-ylmethyl)-amide;

3-Biphenyl-4-ylmethyl-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinoline-6-  
carboxylic acid 3-fluoro-benzyl amide;

25 5-Methyl-7-(4-methylsulfanyl-benzyl)-6-oxo-5,6,7,8-tetrahydro-  
[1,5]naphthyridine-2-carboxylic acid (thiazol-2-ylmethyl)-amide;

7-(3-Chloro-benzylidene)-5-methyl-6-oxo-5,6,7,8-tetrahydro-  
[1,5]naphthyridine-2-carboxylic acid benzylamide;

3-(3-Hydroxy-benzylidene)-1-methyl-2-oxo-1,2,3,4-tetrahydro-  
[1,7]naphthridine-6-carboxylic acid (pyridin-4-ylmethyl)-amide;

30 4-(1-Methyl-2-oxo-6-[(pyridin-3-ylmethyl)-carbamoyl]-1,2,3,4-tetrahydro-  
[1,7]naphthyridin-3-ylmethyl)-benzoic acid;

6-(4-Methanesufanyl-benzyl)-8-methyl-7-oxo-5,6,7,8-tetrahydro-  
[1,8]naphthyridine-3-carboxylic acid-4-cyano-benzylamide;



- 6-(3-Bromo-benzyl)-8-methyl-7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-carboxylic acid 4-fluoro-benzylamide;  
4-Methyl-3-oxo-2-(4-trifluoromethyl-benzylidene)-3,4-dihydro-2H-benzo[1,4]oxazine-7-carboxylic acid 3-methoxy-benzylamide;  
5 2-Benzyl-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-7-carboxylic acid benzylamide;  
2-(3-Chloro-4-fluoro-benzyl)-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-7-carboxylic acid (quinolin-3-ylmethyl)-amide;  
3-Benzylidene-1-methyl-2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxylic acid benzylamide;  
10 4-Methyl-3-oxo-2-thiophen-2-ylmethyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-7-carboxylic acid 4-fluoro-benzylamide;  
4-Methyl-2-(4-methyl-benzylidene)-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-7-carboxylic acid 4-cyano-benzylamide;  
15 2-(4-Chloro-benzyl)-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-7-carboxylic acid-benzylamide;  
4-Methyl-3-oxo-2-pyridin-3-ylmethyl-3,4-dihydro-2H-benzo[1,4]thiazine-7-carboxylic acid (pyridin-4-ylmethyl)-amide;  
2-Furan-2-ylmethyl-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-7-carboxylic acid 4-methoxy-benzylamide;  
20 3-(3-Chloro-benzyl)-1-methyl-2-oxo-2,3-dihydro-1H-pyrido[2,3-b]thiazine-6-carboxylic acid (thiazol-2-ylmethyl)-amide;  
2-Furan-2-ylmethylene-4-methyl-3-oxo-3,4-dihydro-2H-pyrido[4,3-b][1,4]thiazine-7-carboxylic acid (pyridin-4-ylmethyl)-amide; and  
25 2-Benzyl-4-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-7-carboxylic acid 3-methoxy-benzylamide;  
or a pharmaceutically acceptable salt thereof.
11. The compound according to Claim 1, selected from:  
30 3-Benzofuran-6-ylmethyl-6-[3-(4-chloro-phenyl-prop-1-ynyl)]-1-methyl-3,4-dihydro-1H-quinolin-2-one;  
1-Methyl-6-(3-pyrazol-1-yl-prop-1-ynyl)-3-thiophen-2-ylmethyl-3,4-dihydro-1H-[1,8]naphthyridin-2-one;

- 3-(3-Chlorobenzyl)-1-methyl-6-(3-phenyl-prop-1-ynyl)-3,4-dihydro-1H-[1,5]naphthyridin-2-one;
- 3-Furan-2-ylmethyl-6-(3-imidazol-1-yl-prop-1-ynyl)-1-methyl-3,4-dihydro-1H-[1,7]naphthyridin-2-one;
- 5 6-[3-(4-Chloro-phenyl)-prop-1-ynyl]-1-methyl-3-pyridin-4-ylmethyl-1H-pyrido[2,3-b][1,4]oxazin-2-one;
- 4-Methyl-7-(3-pyrazol-1-yl-prop-1-ynyl)-2-thiophen-2-ylmethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one;
- 4-[4-Methyl-3-oxo-7-(3-phenyl-prop-1-ynyl)-3,4-dihydro-2H-benzo[1,4]oxazin-2-ylmethyl]-benzoic acid;
- 10 3-(3-Chloro-benzyl)-methyl-6-(3-phenyl-prop-1-ynyl)-1H-pyrido[2,3-b][1,4]thiazin-2-one;
- 2-Furan-2-ylmethyl-7-(3-imidazol-1-yl-prop-1-ynyl)-4-methyl-4H-pyrido[4,3-b][1,4]thiazin-3-one;
- 15 2-Benzyl-4-methyl-7-(3-[1,2,4]triazol-1-yl-prop-1-ynyl)-4H-pyrido[4,3-b][1,4]thiazin-3-one;
- 2-Benzyl-4-methyl-7-phenylethynyl-4H-pyrido[3,2-b][thiazin-3-one;
- 2-(4-Methanesulfonyl-benzyl)-4-methyl-7-(3-pyridin-3-yl-prop-1-ynyl)-4H-benzo[1,4]thiazin-3-one;
- 20 3-(3-Chloro-benzyl)-1-methyl-4,4-dioxo-6-(3-phenyl-prop-1-ynyl)-3,4-dihydro-1H-4 $\lambda^6$ -pyrido[2,3-b][1,4]thiazin-2-one;
- 2-Furan-2-ylmethyl-7-(3-imidazol-1-yl-prop-1-ynyl)-4-methyl-1,1-dioxo-1,4-dihydro-2H-1 $\lambda^6$ -pyrido[4,3-b][1,4]thiazin-3-one;
- 2-Benzyl-4-methyl-1,1-dioxo-7-(3-[1,2,4]triazol-1-yl-prop-1-ynyl)-1,4-dihydro-2H-1 $\lambda^6$ -pyrido[4,3-b][1,4]thiazin-3-one;
- 25 2-Benzyl-4-methyl-1,1-dioxo-7-phenylethynyl-1,4-dihydro-2H-1 $\lambda^6$ -pyrido[3,2-b][thiazin-3-one; and
- 2-(4-Methanesulfonyl-benzyl)-4-methyl-1,1-dioxo-7-(3-pyridin-3-yl-prop-1-ynyl)-1,4-dihydro-2H-1 $\lambda^6$ -benzo[1,4]thiazin-3-one;
- 30 or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition, comprising a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.
- 5 13. The pharmaceutical composition according to Claim 12, comprising a compound according to Claim 10 or 11, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.
- 10 14. A method for treating arthritis, comprising administering to a patient suffering from an arthritis disease a nontoxic antiarthritic effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 15 15. The method of treating according to Claim 14, wherein the arthritis is osteoarthritis or rheumatoid arthritis.
16. The method according to Claim 15, wherein the compound administered is a compound according to Claim 10 or 11, or a pharmaceutically acceptable salt thereof.